4 Health Care Stock Stories Causing a Midweek Buzz
Merck & Co. (NYSE:MRK): Closing price $45.25
A Merck spokeswoman said Tuesday that the company will resume sales of its controversial Zilmax animal feed additive in the United States and Canada once it finalizes an audit of the manner in which the product is used. Merck ceased sales of the muscle-building drug in August, after Tyson Foods Inc. said it would no longer accept Zilmax-fed beef since some cattle were noticed arriving for slaughter with signs they were having difficulty walking or even moving. Merck said that it stands behind the safety of its product, but the hiatus added to global worries regarding its use.